Olaparib is a PARP (poly ADP ribose polymerase) inhibitor. Cancers related to BRCA 1 or 2 mutations seem to rely on PARP to repair damaged DNA in cancer cells, allowing them to continue to divide. By inhibiting PARP, tumor growth may be slowed or stopped.
Rucaparib is a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor. Cancers related to BRCA 1 or 2 mutations seem to rely on PARP to repair damaged DNA in cancer cells, allowing them to continue to divide. By inhibiting PARP, tumor growth may be slowed or stopped. A blood test is required prior to starting treatment with rucaparib to determine if you have a BRCA mutation.
Niraparib is a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor. Cancers related to BRCA 1 or 2 mutations seem to rely on PARP to repair damaged DNA in cancer cells, allowing them to continue to divide. By inhibiting PARP, tumor growth may be slowed or stopped.